《Cell》期刊發(fā)表這一篇題為“Changes of Cell Biochemical States Are Revealed in Protein Homomeric Complex Dynamics”的文章，揭示了二甲雙胍在細(xì)胞內(nèi)的作用細(xì)節(jié)，進(jìn)一步解釋了二甲雙胍在預(yù)防各種慢性疾病上的潛力，包括癌癥。

       來(lái)自蒙特利爾大學(xué)、倫敦Francis Crick研究所的科學(xué)家們發(fā)現(xiàn)，二甲雙胍會(huì)讓細(xì)胞呈現(xiàn)出類似于缺乏鐵元素的狀態(tài)。這種模擬“鐵饑餓”的方式可以促進(jìn)細(xì)胞更好地?cái)z取、使用葡萄糖，從而實(shí)現(xiàn)了防治效果。

http://www.giant-bio.com/home-productinfo-id-8.html

模擬缺鐵，促進(jìn)糖代謝

      蒙特利爾大學(xué)的生物化學(xué)教授Stephen Michnick帶領(lǐng)團(tuán)隊(duì)開(kāi)發(fā)了一種新技術(shù)——hdPCA，能夠以非侵入性的廉價(jià)方式，快速預(yù)測(cè)和確認(rèn)藥物是如何影響細(xì)胞的。

       他們發(fā)現(xiàn)，二甲雙胍對(duì)于細(xì)胞內(nèi)鐵的分布有著***的影響，進(jìn)而導(dǎo)致基本的生化過(guò)程發(fā)生變化。早前已有研究表明鐵代謝和糖尿病之間存在關(guān)聯(lián)，但是卻沒(méi)有直接的證據(jù)?；?**新的發(fā)現(xiàn)，研究人員推測(cè)，二甲雙胍引發(fā)的葡萄糖代謝可能依賴于模擬缺鐵引發(fā)的化學(xué)反應(yīng)。

      研究人員強(qiáng)調(diào)，仍然需要進(jìn)一步的細(xì)胞和動(dòng)物試驗(yàn)，以確定二甲雙胍模擬鐵饑餓對(duì)葡萄糖代謝的重要性。這將有利于更好地利用這種機(jī)制來(lái)改善糖尿病治。

      作為治二型糖尿病的一線藥物，二甲雙胍的療效已經(jīng)得到了毫無(wú)爭(zhēng)議的認(rèn)可。2017年，《Nature Medicine》期刊發(fā)文揭示了二甲雙胍的降糖作用可能與改變腸道細(xì)菌組成有關(guān)。他們發(fā)現(xiàn)，通過(guò)降低肝臟中葡萄糖的數(shù)量來(lái)治糖尿病并不是二甲雙胍的全部機(jī)制。

      這篇研究指明，二甲雙胍至少在一定程度上通過(guò)促進(jìn)腸道細(xì)菌（如Akkermansia）的生長(zhǎng)來(lái)發(fā)揮作用。這為患者通過(guò)改變飲食來(lái)調(diào)整腸道菌群結(jié)構(gòu)，***終獲得降糖效益提供了新的線索。

除了影響腸道菌群，來(lái)自西北大學(xué)的Navdeep Chandel教授曾證實(shí)，二甲雙胍可以減緩線粒體代謝，進(jìn)而阻止癌癥的生長(zhǎng)。

RNA提取磁珠屬于納米生物磁珠的一種，主要作用是用于核酸提取過(guò)程中的RNA提取，粒徑分布在500nm左右，是洛陽(yáng)吉恩特生物自主研發(fā)生產(chǎn)的高分子納米磁性微球，該磁珠懸浮時(shí)間長(zhǎng)，磁響應(yīng)時(shí)間迅速，對(duì)DNA甲基化過(guò)程中的提取環(huán)節(jié)提供良好的支持，可明顯縮短實(shí)驗(yàn)時(shí)間，提高實(shí)驗(yàn)效率，并在提取結(jié)果上保持穩(wěn)定，配合核酸提取儀，更能實(shí)現(xiàn)快速的RNA提取。

Santa Clara, CA, July 18, 2011 Cell Biosciences, Inc. today announced that it has changed its name to ProteinSimple to clearly reflect the Company's core mission in protein research.

The Company's goal is simply to help researchers gain a better understanding of proteins and their role in disease. ProteinSimple's strategy is to power protein research by making it simpler and more quantitative, ultimately revealing new insights into the true nature of proteins.

Over the past 3 years, ProteinSimple has built a unique portfolio of protein analysis tools including systems for traditional protein imaging, systems to probe the structure and purity of protein based therapeutics and systems that provide fresh insight into protein signaling. Later this year, the Company will launch a revolutionary product that is expected to completely reinvent and automate the Western Blot the most widely used technique in protein analysis.

The company expects to generate over $40 million in revenue in 2011, and has grown significantly from $1 million in 2008. ProteinSimple has over 170 employees and more than 10,000 systems installed around the world. In the last 18 months, the Company has made 4 acquisitions in the protein analysis space and raised over $60 million in venture capital.

“We are all very excited about our new ProteinSimple identity,” commented Tim Harkness, President and CEO of ProteinSimple. “After a period of tremendous growth and change, we felt it was important to speak clearly to our customers about our vision and goals. ProteinSimple captures our entire value proposition and culture in a single word. The employees of ProteinSimple are fully committed to helping researchers gain a deeper understanding of proteins and to building a unique protein analysis pure-play.”

About ProteinSimple

ProteinSimple's goal is simply to help researchers gain a better understanding of proteins and their role in disease. The Company's strategy is to power protein research by making it simpler and more quantitative, ultimately revealing new insights into the true nature of proteins. ProteinSimple has built a unique portfolio of protein analysis tools including systems for traditional protein imaging, systems to probe the structure and purity of protein based therapeutics and systems that provide fresh insight into protein signaling. ProteinSimple has over 170 employees, more than 10,000 systems installed around the world and is headquartered in Santa Clara, California. For more information, visit www.proteinsimple.com.

Santa Clara, CA, September 8, 2009 Cell Biosciences, Inc. today announced that it has completed its acquisition of Alpha Innotech Corp. (OTC BB: APNO.OB). The stockholders of Alpha Innotech have approved the transaction, and all regulatory and other conditions have been satisfied. Pursuant to the merger agreement announced on September 8, 2009, former Alpha Innotech stockholders will receive $1.50 per share, or approximately $17.9 million in cash.


(Cell Biosciences hasChanged Name to ProteinSimple.)